Indian Journal of Gastroenterology

, Volume 38, Issue 1, pp 44–54 | Cite as

Effectiveness and safety of adalimumab biosimilar in inflammatory bowel disease: A multicenter study

  • Nagesh Kamat
  • Saurabh Kedia
  • Uday C. Ghoshal
  • Abhimanyu Nehra
  • Govind Makharia
  • Ajit Sood
  • Vandana Midha
  • Varun Gupta
  • Gourdas Choudhuri
  • Vineet AhujaEmail author
Original Article



Adalimumab has emerged as a useful drug for treating patients with Crohn’s disease (CD) and ulcerative colitis (UC), not responding to conventional therapy. There is limited data on effectiveness and safety of adalimumab biosimilar in patients with inflammatory bowel disease (IBD).


Patients with IBD who received at least one dose of adalimumab biosimilar from October 2015 to February 2018 were retrospectively included in this multicenter data analysis. Its effectiveness in inducing and maintaining clinical remission at 8, 26, and 52 weeks for CD and UC and safety profile of the drug was studied.


Seventy patients (49 CD; 21 UC) with a median age of 39 (range 13–73) years, male predominance (64.3%), and median (IQR) disease duration of 72 (33–104) months were included. Adalimumab biosimilar was effective in inducing remission (at 8 weeks) in 46.9% and 52.4% patients with CD and UC, respectively, of whom  32.7% and 33.3% (three fourths of remitters) maintained remission over 1 year, respectively. Twenty (28.6%) patients experienced adverse events; seven (10%) were serious of whom  three had developed tuberculosis.


Adalimumab biosimilar in usual clinical practice is safe and effective in inducing and maintaining remission in Indian patients with IBD. Steroid-free clinical remission was observed in one third of patients with UC and CD at 1 year of therapy.

Graphical Abstract


Adalimumab Biosimilar Efficacy Inflammatory bowel disease Safety 


Compliance with ethical standards

Conflict of interest

NK, SK, UCG, AN, GM, AS, VM, VG, GC and VA declare that they have no conflict of interest.

Ethics statement

The study was performed in a manner to conform with the Helsinki Declaration of 1975, as revised in 2000 and 2008 concerning human and animal rights. The study protocol was approved by the institutional review board and ethics committee of the coordinating center.


The authors are solely responsible for the data and the content of the paper. In no way the Honorary Editor-in-Chief, Editorial Board Members, or the printer/publishers are responsible for the results/findings and content of this article.


  1. 1.
    Abraham C, Cho JH. Inflammatory bowel disease. N Engl J Med. 2009;361:2066–78.CrossRefPubMedPubMedCentralGoogle Scholar
  2. 2.
    Kedia S, Ahuja V. Epidemiology of inflammatory bowel disease in India: the Great Shift East. Inflamm Intest Dis. 2017;2:102–15.CrossRefPubMedPubMedCentralGoogle Scholar
  3. 3.
    Ahuja V, Tandon RK. Inflammatory bowel disease in the Asia-Pacific area: a comparison with developed countries and regional differences. J Dig Dis. 2010;11:134–47.CrossRefPubMedGoogle Scholar
  4. 4.
    Singh P, Ananthakrishnan A, Ahuja V. Pivot to Asia: inflammatory bowel disease burden. Intest Res. 2017;15:138–41.CrossRefPubMedPubMedCentralGoogle Scholar
  5. 5.
    Panés J, O’Connor M, Peyrin-Biroulet L, Irving P, Petersson J, Colombel JF. Improving quality of care in inflammatory bowel disease: what changes can be made today? J Crohns Colitis. 2014;8:919–26.CrossRefPubMedGoogle Scholar
  6. 6.
    Kamat N, Rajan Mallayasamy S, Sharma PSVN, Kamath A, Pai CG. Video assisted patient education improves compliance with follow up and depression scores in inflammatory bowel diseases. Postgrad Med. 2018;130:355–60.Google Scholar
  7. 7.
    Colombel J, Sandborn W, Rutgreerts P, Enns R. Adalimumab for maintenance of clinical response and remission in patients with Crohn’s disease: the CHARM trial. Gastroenterology. 2007;132:52–65.CrossRefPubMedGoogle Scholar
  8. 8.
    Wasan SK, Kane SV. Adalimumab for the treatment of inflammatory bowel disease. Expert Rev Gastroenterol Hepatol. 2011;5:679–84.CrossRefPubMedGoogle Scholar
  9. 9.
    Colombel JF, Sandborn WJ, Ghosh S, et al. Four-year maintenance treatment with adalimumab in patients with moderately to severely active ulcerative colitis: data from ULTRA 1, 2, and 3. Am J Gastroenterol. 2014;109:1771–80.CrossRefPubMedPubMedCentralGoogle Scholar
  10. 10.
    Midha V, Mahajan R, Mehta V, et al. Efficacy and safety of the adalimumab biosimilar Exemptia as induction therapy in moderate-to-severe ulcerative colitis. Intest Res. 2018;16:83–9.CrossRefPubMedPubMedCentralGoogle Scholar
  11. 11.
    Dignass A, Eliakim R, Magro F, et al. Second European evidence-based consensus on the diagnosis and management of ulcerative colitis part 1: definitions and diagnosis. J Crohns Colitis. 2012;6:965–90.CrossRefPubMedGoogle Scholar
  12. 12.
    Van Assche G, Dignass A, Panes J, et al. The second European evidence-based consensus on the diagnosis and management of Crohn’s disease: definitions and diagnosis. J Crohns Colitis. 2010;4:7–27.CrossRefPubMedGoogle Scholar
  13. 13.
    Silverberg MS, Satsangi J, Ahmad T, et al. Toward an integrated clinical, molecular and serological classification of inflammatory bowel disease: report of a Working Party of the 2005 Montreal World Congress of Gastroenterology. Can J Gastroenterol. 2005;19 Suppl A:5A–36A.CrossRefPubMedGoogle Scholar
  14. 14.
    Walmsley RS, Ayres RC, Pounder RE, Allan RN. A simple clinical colitis activity index. Gut. 1998;43:29–32.CrossRefPubMedPubMedCentralGoogle Scholar
  15. 15.
    Best WR, Becktel JM, Singleton JW, Kern F. Development of a Crohn’s disease activity index. National Cooperative Crohn’s Disease Study. Gastroenterology. 1976;70:439–44.CrossRefPubMedGoogle Scholar
  16. 16.
    Sandborn WJ, Feagan BG, Hanauer SB, et al. A review of activity indices and efficacy endpoints for clinical trials of medical therapy in adults with Crohn’s disease. Gastroenterology. 2002;122:512–30.CrossRefPubMedGoogle Scholar
  17. 17.
    Osterman MT. Mucosal healing in inflammatory bowel disease. J Clin Gastroenterol. 2013;47:212–21.CrossRefPubMedGoogle Scholar
  18. 18.
    Schluger NW, Burzynski J. Recent advances in testing for latent TB. Chest. 2010;138:1456–63.CrossRefPubMedPubMedCentralGoogle Scholar
  19. 19.
    Pai M, Denkinger CM, Kik SV, et al. Gamma interferon release assays for detection of Mycobacterium tuberculosis infection. Clin Microbiol Rev. 2014;27:3–20.CrossRefPubMedPubMedCentralGoogle Scholar
  20. 20.
    WHO | Latent tuberculosis infection (LTBI) [Internet]. WHO. [cited 2018 Feb 5]. Available from:
  21. 21.
    Information NC for B, Pike USNL of M 8600 R, MD B, Usa 20894. Case definitions [Internet]. World Health Organization; 2010 [cited 2017 Dec 6]. Available from:
  22. 22.
    Kedia S, Ahuja V. Is the emergence of inflammatory bowel disease a prime example of “the third epidemiological transition”? Indian J Gastroenterol. 2018;37:183–5.CrossRefPubMedGoogle Scholar
  23. 23.
    Ahuja V, Tandon RK. Inflammatory bowel disease: the Indian augury. Indian J Gastroenterol. 2012;31:294–6.CrossRefPubMedGoogle Scholar
  24. 24.
    Agarwal A, Kedia S, Jain S, et al. Very high rate of tuberculosis complicating infliximab therapy for inflammatory bowel disease despite tuberculosis screening in India. Intest Res. 2018;16:588–98.CrossRefPubMedPubMedCentralGoogle Scholar
  25. 25.
    Hanauer S, Sandborn W, Rutgeerts P, et al. Human anti-tumour necrosis factor monoclonal antibody (adalimumab) in Crohn’s disease: the CLASSIC-I trial. Gastroenterology. 2006;130:323–33.CrossRefPubMedGoogle Scholar
  26. 26.
    Reinisch W, Sandborn WJ, Hommes DW, et al. Adalimumab for induction of clinical remission in moderately to severely active ulcerative colitis: results of a randomised controlled trial. Gut. 2011;60:780–7.CrossRefPubMedGoogle Scholar
  27. 27.
    Sandborn WJ, van Assche G, Reinisch W, et al. Adalimumab induces and maintains clinical remission in patients with moderate-to-severe ulcerative colitis. Gastroenterology. 2012;142:257–65.CrossRefPubMedGoogle Scholar
  28. 28.
    Suzuki Y, Motoya S, Hanai H, et al. Efficacy and safety of adalimumab in Japanese patients with moderately to severely active ulcerative colitis. J Gastroenterol. 2014;49:283–94.CrossRefPubMedGoogle Scholar
  29. 29.
    Travis S, Feagan BG, Peyrin-Biroulet L, et al. Effect of adalimumab on clinical outcomes and health-related quality of life among patients with ulcerative colitis in a clinical practice setting: results from InspirADA. J Crohns Colitis. 2017;11:1317–25.CrossRefPubMedPubMedCentralGoogle Scholar
  30. 30.
    Van de Vondel S, Baert F, Reenaers C, et al. Incidence and predictors of success of adalimumab dose escalation and De-escalation in ulcerative colitis: a real-world Belgian cohort study. Inflamm Bowel Dis. 2018;24:1099–105.CrossRefGoogle Scholar
  31. 31.
    Zacharias P, Damião AOMC, Moraes AC, et al. Adalimumab for ulcerative colitis: results of a Brazilian multicenter observational study. Arq Gastroenterol. 2017;54:321–7.CrossRefPubMedGoogle Scholar
  32. 32.
    Thorlund K, Druyts E, Mills EJ, Fedorak RN, Marshall JK. Adalimumab versus infliximab for the treatment of moderate to severe ulcerative colitis in adult patients naive to anti-TNF therapy: an indirect treatment comparison meta-analysis. J Crohns Colitis. 2014;8:571–81.CrossRefPubMedGoogle Scholar
  33. 33.
    Rutgeerts P, Sandborn WJ, Feagan BG, et al. Infliximab for induction and maintenance therapy for ulcerative coliti. N Engl J Med. 2005;353:2462–76.CrossRefGoogle Scholar
  34. 34.
    Song WJ, Kang B, Choi SY, Choe YH. Adalimumab treatment in pediatric-onset Crohn’s disease patients after infliximab failure: a single center study. Pediatr Gastroenterol Hepatol Nutr. 2016;19:116–22.CrossRefPubMedPubMedCentralGoogle Scholar
  35. 35.
    Taxonera C, Estelles J, Fernandez-Blanco I, et al. Adalimumab induction and maintenance therapy for patients with ulcerative colitis previously treated with infliximab. Aliment Pharmacol Ther. 2011;33:340–8.CrossRefPubMedGoogle Scholar
  36. 36.
    Rutgeerts P, Sandborn WJ, Enns R, et al. Adalimumab rapidly induces clinical response and remission in patients with moderate to severe Crohn’s disease who had secondary failure to infliximab therapy: results of the GAIN study. Gut. 2006;55 Suppl:A20.Google Scholar
  37. 37.
    Mazor Y, Almog R, Kopylov U, et al. Adalimumab drug and antibody levels as predictors of clinical and laboratory response in patients with Crohn’s disease. Aliment Pharmacol Ther. 2014;40:620–8.CrossRefPubMedGoogle Scholar
  38. 38.
    Hindryckx P, Novak G, Bonovas S, Peyrin-Biroulet L, Danese S. Infection risk with biologic therapy in patients with inflammatory bowel disease. Clin Pharmacol Ther. 2017;102:633–41.CrossRefPubMedGoogle Scholar
  39. 39.
    Kamat N, Ganesh Pai C, Surulivel Rajan M, Kamath A. Cost of illness in inflammatory bowel disease. Dig Dis Sci. 2017;62:2318–26.CrossRefPubMedGoogle Scholar

Copyright information

© Indian Society of Gastroenterology 2019

Authors and Affiliations

  • Nagesh Kamat
    • 1
  • Saurabh Kedia
    • 1
  • Uday C. Ghoshal
    • 2
  • Abhimanyu Nehra
    • 2
  • Govind Makharia
    • 1
  • Ajit Sood
    • 3
  • Vandana Midha
    • 3
  • Varun Gupta
    • 4
  • Gourdas Choudhuri
    • 4
  • Vineet Ahuja
    • 1
    Email author
  1. 1.Department of GastroenterologyAll India Institute of Medical SciencesNew DelhiIndia
  2. 2.Department of GastroenterologySanjay Gandhi Postgraduate Institute of Medical SciencesLucknowIndia
  3. 3.Department of GastroenterologyDayanand Medical College and HospitalLudhianaIndia
  4. 4.Department of GastroenterologyFortis Memorial Research InstituteGurugramIndia

Personalised recommendations